OneCell Diagnostics is now 1Cell.Ai

Liquid Biopsy Reveals ERBB3-PIK3CA Activation and MYC Amplification Driving Resistance in Metastatic Cervical Cancer

Clinical History & Chronological Summary

  • Diagnosis: 50 y/ female diagnosed with poorly differentiated squamous cell carcinoma of cervix
  • Initial Treatment: Initially treated with chemotherapy, brachytherapy, radiotherapy. Later, disease recurrence with multiple
    nodal mets -> Pac+Carbo+Bev. Further progression, treated with Gem+Nab-Pac.
  • Further evaluation: Presently on Pem+Carbo+ZA. Comprehensive molecular profiling via OncoIndx Liquid Biopsy to understand
    molecular cause for recurrence and aggressiveness and identify possible treatment resistance and directives

 

Clinical Challenges

  • Recurrent, metastatic disease: Initial squamous cell carcinoma of cervix treated with definitive chemoradiation involving multiple nodal metastases, indicating systemic relapse and need for dynamic disease monitoring
  • Heavily pretreated setting raises concern for evolving resistance clones and limited tissue access
  • Recent Pem exposure in a low-TMB/MSS tumour raises concerns regarding sustained immunotherapy efficacy, thereby warranting serial ctDNA assessment to detect emergent targetable alterations or resistance-conferring variants.

Download Our Case Study

1Cell.Ai
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.